Evommune, Inc. Lease, Cost
Evommune, Inc. (EVMN) reported Lease, Cost of $1.81 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-06
- Evommune, Inc. lease, cost for the quarter ending 2026-06-30 was $1.11M, a 70.09% increase year-over-year.
- Evommune, Inc. lease, cost for the quarter ending 2026-03-31 was $705.00K, a 8.13% increase year-over-year.
- Evommune, Inc. lease, cost for the quarter ending 2025-12-31 was $635.00K, a 12.77% decline year-over-year.
- Evommune, Inc. lease, cost for the quarter ending 2025-09-30 was $656.00K.
- Evommune, Inc. lease, cost for fiscal 2025 was $2.60M, a 9.40% increase from fiscal 2024.
- Evommune, Inc. lease, cost for fiscal 2024 was $2.37M.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.81M 10-Q · filed 2026-08-06 | $2.45M derived: sum of 3 quarters · filed 2026-08-06 | $3.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $705.00K 10-Q · filed 2026-05-07 | $1.34M derived: sum of 2 quarters · filed 2026-05-07 | $2.00M derived: sum of 3 quarters · filed 2026-05-07 | $2.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $635.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.29M derived: sum of 2 quarters · filed 2026-03-05 | $1.94M derived: sum of 3 quarters · filed 2026-08-06 | $2.60M 10-K · filed 2026-03-05 |
| 2025-09-30 | $656.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-12-11 | $1.31M derived: sum of 2 quarters · filed 2026-08-06 | $1.96M 10-Q · filed 2025-12-11 | $2.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $652.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.30M 10-Q · filed 2026-08-06 | $2.03M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-03-31 | $652.00K 10-Q · filed 2026-05-07 | $1.38M derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $728.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.37M 10-K · filed 2026-03-05 | ||
| 2024-09-30 | $1.64M 10-Q · filed 2025-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |